PTSD and depression research
Amount
6.8 mg
Frequency
Single dose
Duration
Single administration
Route
IntranasalTiming
Delivered via nasal atomizer device; intranasal route bypasses blood-brain barrier for direct CNS delivery
Duration
Single dose
Repeatable
Yes
CBC with differential
When: Baseline
Why: Baseline blood cell counts
CMP (Comprehensive Metabolic Panel)
When: Baseline
Why: Baseline metabolic panel
Get free access to all content plus biweekly research updates.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Neuropeptide Y (NPY) is a 36-amino acid peptide amide first isolated from porcine brain by Tatemoto and colleagues in 1982. It belongs to the pancreatic polypeptide family alongside peptide YY (PYY) and pancreatic polypeptide (PP). NPY is one of the most abundant neuropeptides in the mammalian brain, with particularly high concentrations in the hypothalamus, amygdala, hippocampus, and cortex.
NPY plays critical roles in appetite regulation, stress response, anxiety modulation, circadian rhythms, and cardiovascular function. Its involvement in stress resilience has made it a target for PTSD and depression research.
NPY exerts its effects through a family of five G protein-coupled receptors (Y1-Y5), of which four (Y1, Y2, Y4, Y5) are functionally active in humans:
NPY research spans basic neuroscience, neuroendocrinology, and translational psychiatry. Key findings include the discovery that NPY levels correlate with stress resilience in military populations, reduced CSF NPY in PTSD and depression patients, and preliminary clinical evidence that intranasal NPY may have rapid antidepressant effects.
NPY is an endogenous peptide with complex, receptor subtype-specific, and brain region-dependent effects. Its roles in appetite stimulation and cardiovascular regulation present potential complications for therapeutic use. Clinical development is at an early stage with small proof-of-concept trials, and NPY does not cross the blood-brain barrier efficiently without intranasal delivery.
Neuropeptide Y: complete amino acid sequence of the brain peptide, published in Proceedings of the National Academy of Sciences (Tatemoto K et al., 1982; PMID: 6957876):
Original characterization of neuropeptide Y isolated from porcine brain. Determined the complete 36-amino acid sequence and identified structural similarities to peptide YY and pancreatic polypeptide.
A randomized controlled trial of intranasal neuropeptide Y in patients with major depressive disorder, published in International Journal of Neuropsychopharmacology (Sayed S et al., 2020; PMID: 33009815):
Randomized double-blind placebo-controlled trial of single intranasal NPY (6.8 mg) in 30 MDD patients on stable antidepressants. Showed preliminary antidepressant effects assessed over 48 hours.
We summarize new studies, safety updates, and dosing insights โ delivered biweekly.
See real-world usage patterns alongside the clinical evidence above. Community-sourced, not clinically verified.
Based on 3+ community reports
View community protocolsSemax peptide guide: not FDA approved, but used in Russia since 2011. Covers BDNF upregulation, stroke recovery data, intranasal dosing, and safety risks.
Selank: Tuftsin-derived anxiolytic nootropic peptide. Covers GABA modulation, anti-anxiety effects, cognitive enhancement, intranasal dosing, and safety.
DSIP: Delta sleep-inducing nonapeptide guide. Covers EEG sleep effects, stress hormone modulation, opioid withdrawal research, dosing, and safety.
Dihexa (PNB-0408): angiotensin IV-derived peptide that potentiates HGF/c-Met signaling. Covers preclinical cognitive enhancement research, oral bioavailability, and safety considerations.
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.
Related content you may find interesting
